Close

Help us reach $1,000,000! Match My Donation

Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

img_table4_Oncolytic.pngOncolytic virus immununotherapy uses a modified virus that can both cause tumor cells to self destruct and activate a greater immune response
How does it work?

  • Oncolytic viruses are viruses that directly kill (“lyse”) cancer cells and can also activate cells of the immune system, such as dendritic cells and T cells, to target and eliminate cancer throughout the body
  • Sometimes, oncolytic viruses are genetically modified to produce immune-stimulating chemicals, or to make them more specific for cancer cells
  • Oncolytic virus immunotherapies are often combined with other types of cancer immunotherapies, including therapeutic cancer vaccines and mAb therapy

For which cancers is it currently being used or being studied?

  • No oncolytic virus immunotherapy is FDA approved.
  • Oncolytic virus immunotherapies are currently being studied in clinical trials for a number of cancers, including:
    • CG0070 (bladder)
    • Reolysin (prostate, colorectal, ovarian, lung, and breast)
    • CAVATAK (melanoma)
    • JX-594 (ovarian)
    • MV-NIS (multiple myeloma)
    • T-VEC (melanoma)
    • And many more

*Immunotherapy results may vary from patient to patient.

Contact Us

Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Patient education information supported by a charitable donation from Bristol-Myers Squibb Company.
Top